Digest Network Come funziona
Network
/
Società
Ha
Non verificato

Hansa Biopharma AB

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaImpreseSanità

23 comunicati stampa

Guarda tutti i comunicati
29/07/2025
Salute
Fitness
Medicina - Varie
Hansa Biopharma announces key executive appointments to support continued growth
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
17/07/2025
Salute
Fitness
Economia
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
08/07/2025
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
11/06/2025
Salute
Fitness
Fiere
Eventi
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Hansa Biopharma to attend BIO International Convention
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
09/06/2025
Farmaceutica
Sanità
Media
Comunicazione
Multimedialità
Editoria elettronica
Biologia
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
14/05/2025
Farmaceutica
Banca
Sanità
Economia
Start-up
Finanza
Biologia
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
13/05/2025
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
24/04/2025
Farmaceutica
Sanità
Imprese
Biologia
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
21/03/2025
Farmaceutica
Sanità
Economia
Biologia
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0
11/03/2025
Farmaceutica
Sanità
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0